English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims  Heart failure ( HF ) treatment guided by physicians with access to real‐time pressure measurement from a wireless implantable pulmonary artery pressure ( PAP ) sensor ( CardioMEMS ), has previously been shown to reduce HF‐related hospital admissions in the  CHAMPION  trial. However, uncertainty remains regarding the value of  CardioMEMS  in European health systems where healthcare costs are significantly lower than in the  USA .    Methods and results  A Markov model was developed to estimate the cost‐effectiveness of  PAP ‐guided treatment of  HF  using the  CardioMEMS ™  HF  system compared with usual care. Cost‐effectiveness was measured as the incremental cost per quality‐adjusted life year ( QALY ) gained. In the base case analysis over a time horizon of 10 years,  PAP ‐guided  HF  therapy increased cost compared with usual care by £10 916 (€14 030).  QALYs  per patient for usual care and  PAP ‐guided patients were 2.57 and 3.14, respectively, reflecting an increase of 0.57  QALYs  with  PAP ‐guided treatment. The resultant incremental cost‐effectiveness ratio ( ICER ) is £19 274 (€24 772) per  QALY  gained. The base case analysis did not include staff time, due to a lack of data concerning this variable. Running the model with estimated staff time included resulted in an increased  ICER  of between £22 342 and £25 464 per  QALY  gained (€28 709–32 721).    Conclusion  The analysis indicates that integrating wireless  PAP  monitoring into the management of  UK HF  patients is likely to be a cost‐effective addition to the  HF  treatment pathway for appropriate patients.

The cost‐effectiveness of real‐time pulmonary artery pressure monitoring in heart failure patients: a European perspective